Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY). Designed for patients aged 12 and older ...

Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon ...

(RTTNews) - Sanofi (SNYNF, SNY) announced Wednesday that the US Food and Drug Administration has granted fast track designation to the company's mRNA vaccine candidate for the prevention of ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Investing.com -- The US Food and Drug Administration (FDA) has approved Sanofi (NASDAQ: SNY )’s treatment for hemophilia, Qfitlia (fitusiran), which can be administered as infrequently as once every ...

(RTTNews) - Sanofi (SNY), a French pharmaceutical and healthcare company, announced Tuesday that the US Food and Drug Administration is evaluating under priority review the regulatory submission ...

Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple ...

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review for the regulatory submission of tolebrutinib ...